Volume 14 - Issue 6 - June, 2002

Direct Stent Implantation in Acute Coronary Syndrome

Intracoronary stents have been a major milestone in interventional cardiology ever since two large, randomized trials1,2 documented that they reduced restenosis and repeat revascularization rates and increased event-free survival at 6 months. Recent improvements in stent implantation techniques3 and a combination of potent antiplatelet agents,4 such as glycoprotein IIb/IIIa inhibitors, have led to a dramatic improvement in success rate, justifying the stenting of most patients undergoing intervention, even when it is performed in thrombus-containing lesions (which are no longer regarded as les



Pretreatment with Intragraft Verapamil Prior to Percutaneous Coronary Intervention of Saphenous Vein Graft Lesions: Results of t

Intracoronary calcium channel blockers have been administered during percutaneous coronary interventions (PCI) for the management of reduced coronary flow due to microvascular dysfunction.1–3 More recent studies have shown that intracoronary calcium antagonists may improve coronary and myocardial perfusion when given prophylactically prior to elective PCI,4,5 and in patients undergoing primary PCI for acute myocardial infarction.6 In addition to calcium channel blockers, other agents including abciximab,7 adenosine8 and the adenosine triphosphate-sensitive potassium channel opener nicorandil



Acute Coronary Syndromes: Direct Stent for All?

The development of pre-mounted stents, as well as numerous technical enhancements, have contributed to the improvement of stent profile, flexibility and safety. Stent placement without predilation has become feasible and can virtually be carried out by all interventional cardiologists. Indeed, after a number of successful preliminary experiences, the operators have been able to modify their implantation techniques and to start performing direct stenting routinely in selected patients.1–5 In this setting, the questions remain: What patients are eligible for direct stenting? Are there still co



Intragraft Verapamil: “An Ounce of Prevention is Worth a Pound of Cure”

In the current issue of the Journal, Michaels et al.1 provide convincing evidence that the prophylactic administration of verapamil prior to percutaneous coronary intervention (PCI) of saphenous vein grafts

See Michaels et al. on pages 299–302

reduces the incidence of no-reflow and improves myocardial perfusion. From a randomized trial, they provide evidence-based support for a strategy we have employed for almost 3 years. Several caveats to the important observations of Michaels et al. should be noted. First, although the number of patients evaluated is small, the methodology



Comparison of Dilatation Mechanism and Long-Term Vessel Remodeling Between Directional Coronary Atherectomy and Balloon Angiopla

Although acute and late results of coronary intervention have been obtained by coronary angiography and this method might be sufficient for daily practice, angiography is a luminology1 and cannot reveal changes in vessel and plaque volume. On the other hand, use of intravascular ultrasound (IVUS) allows transmural, tomographic imaging of coronary arteries in humans in vivo, providing insight into the pathology of coronary artery disease. Furthermore, the time course of vessel remodeling after directional coronary atherectomy (DCA) has recently been evaluated by volumetric analysis with IVUS.2,



Clinical Evaluation of the SyvekPatch® in Consecutive Patients Undergoing Interventional, EPS and Diagnostic Cardiac Catheteriza

Management of bleeding at the femoral vascular access site following percutaneous catheterization is of paramount importance. Traditionally, manual or mechanical compression has been the standard approach to achieve hemostasis. Prior to this clinical evaluation, the Mt. Sinai Medical Center & Miami Heart Institute’s protocol directed that a sandbag be used to compress the vascular access site for 4–6 hours. Unfortunately, this method has many shortcomings. First, the process is time consuming, labor intensive and costly because it involves several hours of in-hospital observation. Second,



Transcatheter Closure of Congenital and Acquired Muscular Ventricular Septal Defects Using the Amplatzer® Device

Surgical closure of congenital or acquired [post-myocardial infarction (MI)] muscular ventricular septal defects (MVSD) is still associated with significant mortality and long-term morbidity.1,2 Different surgical approaches have been suggested, requiring either a right or left ventriculotomy.3,4 Over the past few years, devices designed originally for percutaneous closure of atrial septal defects or patent ductus arteriosus have been used to close MVSDs with variable degrees of successful closure and residual shunts.5–10 Lock et al.5 first reported the transcatheter occlusion of a VSD using



Direct Stent Implantation in Acute Coronary Syndrome

Intracoronary stents have been a major milestone in interventional cardiology ever since two large, randomized trials1,2 documented that they reduced restenosis and repeat revascularization rates and increased event-free survival at 6 months. Recent improvements in stent implantation techniques3 and a combination of potent antiplatelet agents,4 such as glycoprotein IIb/IIIa inhibitors, have led to a dramatic improvement in success rate, justifying the stenting of most patients undergoing intervention, even when it is performed in thrombus-containing lesions (which are no longer regarded as les



  • « Previous
  •  | Page 1 of 3 | 
  • Next »